母体用药清单为何重要:联合5-羟色胺能暴露致新生儿毒性
本文报道一例在宫内暴露于文拉法辛(一种SNRI)、安非他酮和喹硫平的新生儿,出生后几乎立即出现脑病和异常运动。作者认为症状的严重程度和出现速度可能归因于安非他酮和喹硫平增强了文拉法辛的5-羟色胺能效应。新生儿科医护人员应了解母亲用药情况,并对常见精神药物暴露可能引起的不良反应做好准备。
要点
- 宫内暴露于文拉法辛、安非他酮和喹硫平的新生儿,出生后几乎立即出现脑病和异常运动。
- 症状的严重程度和出现速度可能归因于安非他酮和喹硫平增强了文拉法辛的5-羟色胺能效应。
- 新生儿科医护人员应了解母亲用药,并为常见精神药物暴露的不良反应做准备。
核心结论
- 宫内联合暴露于文拉法辛、安非他酮和喹硫平的新生儿,出生后几乎立即出现脑病和异常运动,症状严重程度和速度可能源于药物对5-羟色胺能效应的增强。
研究设计与样本
- 本文为个案报道,描述一名在宫内暴露于文拉法辛、安非他酮和喹硫平的新生儿。
主要发现
- 该新生儿出生后几乎立即出现脑病和异常运动。
- 作者提出症状的严重程度与出现速度可能归因于安非他酮和喹硫平对文拉法辛5-羟色胺能效应的增强。
临床怎么用
- 新生儿科医护人员应了解母亲的用药清单,并对常见精神药物暴露可能引起的不良反应做好准备。
局限性
- 本文为单个病例报道,未提供样本量、对照或定量风险估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Serotonergic medications are used for the prevention and treatment of depression during pregnancy. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (SNRIs) can cause poor neonatal adaptation, which has been attributed to withdrawal versus toxicity. Bupropion, a norepinephrine-dopamine reuptake inhibitor, is often used as an adjunctive agent to selective serotonin reuptake inhibitors or SNRIs for refractory depression. Quetiapine, an atypical antipsychotic, may also be used in more complex cases. When combined with serotonergic drugs, bupropion and quetiapine are associated with increased risk of serotonin syndrome in adults. We describe a neonate exposed to venlafaxine (an SNRI), bupropion, and quetiapine in utero who presented nearly immediately after birth with encephalopathy and abnormal movements. The severity and rapidity of symptoms may be attributable to potentiation of venlafaxine's serotonergic effects by bupropion and quetiapine. Neonatal providers should be aware of maternal medications and prepare for possible adverse effects, particularly from common psychotropic exposures.
引用
- Brajcich MR, Palau MA, Messer RD, et al. Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. Pediatrics. 2021. PMID: 33504611. doi:10.1542/peds.2019-2250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。